JWH-018

JWH-018

Systematic (IUPAC) name
Naphthalen-1-yl-(1-pentylindol-3-yl)methanone
Clinical data
Legal status	AU: Prohibited (S9) US: Schedule I
Routes of administration	Smoked, Oral
Identifiers
CAS Registry Number	209414-07-3 N
PubChem	CID 10382701
ChemSpider	8558143 Y
ChEMBL	CHEMBL561013 Y
Chemical data
Formula	C24H23NO
Molecular mass	341.45 g/mol
InChI InChI=1S/C24H23NO/c1-2-3-8-16-25-17-22(20-13-6-7-15-23(20)25)24(26)21-14-9-11-18-10-4-5-12-19(18)21/h4-7,9-15,17H,2-3,8,16H2,1H3  Y Key:JDNLPKCAXICMBW-UHFFFAOYSA-N  Y
Physical data
Solubility in water	hydrophobic, n/a mg/mL (20 °C)
N (what is this?)  (verify)

JWH-018 (1-pentyl-3-(1-naphthoyl)indole) or AM-678^[1] is an analgesic chemical from the naphthoylindole family that acts as a full agonist at both the CB₁ and CB₂ cannabinoid receptors, with some selectivity for CB₂. It produces effects in animals similar to those of THC, a cannabinoid naturally present in cannabis, leading to its use in synthetic cannabis products such as "legal cannabis herbal incense blends" which in some countries are sold legally as "incense", labeled "not for human consumption".^{[2][3][4][5][6]}

History

John W. Huffman, an organic chemist at Clemson University, synthesized analogues and metabolites of Δ⁹-tetrahydrocannabinol (THC), the principal active component of cannabis. JWH-018 is one of these analogues, with studies showing an affinity for the cannabinoid (CB₁) receptor five times greater than that of THC. Cannabinoid receptors are found in mammalian brain and spleen tissue; however, the structural details of the active sites are currently unknown.^[7]

On December 15, 2008, it was reported by the German pharmaceutical company THC Pharm that JWH-018 was found as one of the active components in at least three versions of the herbal blend Spice, which has been sold as an incense in a number of countries around the world since 2002.^[8][9][10] An analysis of samples acquired four weeks after the German prohibition of JWH-018 took place found that the compound had been replaced with JWH-073.^[11]

Pharmacology

JWH-018 is a full agonist of both the CB₁ and CB₂ cannabinoid receptors, with a reported binding affinity of 9.00 ± 5.00 nM at CB₁ and 2.94 ± 2.65 nM at CB₂.^[3]

Pharmacokinetics

JWH-018 administered to rats resulted in the excretion of an indole-N-desalkyl metabolite as well as several hydroxylated metabolites in urine. The highest signals were observed for the hydroxylated N-desalkyl metabolites. Hydroxylation took place on the side chain and in both aromatic systems, the naphthalene and the indole rings, as could be shown by mass shift of the corresponding fragments and by MS³ experiments.^[12] Human metabolites were similar although most metabolism took place on the indole ring and pentyl side chain, and the hydroxylated metabolites were extensively conjugated with glucuronide.^[13]

Usage

At least one case of JWH-018 dependence has been reported by the media.^[2] The user consumed JWH-018 daily for eight months. Withdrawal symptoms were similar to those experienced as a result of cannabis dependence. JWH-018 has been shown to cause profound changes in CB₁ receptor density following administration, causing desensitization to its effects more rapidly than related cannabinoids.^[6]

On October 15, 2011, Anderson County coroner Greg Shore attributed the death of a South Carolina college basketball player to "drug toxicity and organ failure" caused by JWH-018.^[14] An email dated Nov 4, 2011 concerning the case was finally released by the city of Anderson S.C. on Dec 16, 2011 under the Freedom of Information Act after multiple requests by media to see the information had been denied.^[15]

Compared to THC, which is a partial agonist at CB₁ receptors, JWH-018 (and many of its analogues) are full agonists. THC has been shown to inhibit GABA receptor neurotransmission in the brain via several pathways.^[16][17] JWH-018 may cause intense anxiety, agitation, and, in rare cases (generally with non-regular JWH users), has been assumed to have been the cause of seizures and convulsions by inhibiting GABA neurotransmission more effectively than THC. Cannabinoid receptor full agonists may present serious dangers to the user when used to excess.^[18]

Various physical and psychological adverse effects have been reported from JWH-018 use. One study reported psychotic relapses and anxiety symptoms in well-treated patients with mental illness following JWH-018 inhalation.^[19] Due to concerns about the potential of JWH-018 and other synthetic cannabinoids to cause psychosis in vulnerable individuals, it has been recommended that people with risk factors for psychotic illnesses (like a past or family history of psychosis) not use these substances.^[20]

Detection in biological fluids

JWH-018 usage is readily detected in urine using "spice" screening immunoassays from several manufacturers focused on both the parent drug and its omega-hydroxy and carboxyl metabolites.^[21] JWH-018 will not be detected by older methods employed for detecting THC and other cannabis terpenoids. Determination of the parent drug in serum or its metabolites in urine has been accomplished by GC-MS or LC-MS. Serum JWH-018 concentrations are generally in the 1–10 μg/L range during the first few hours after recreational usage. The major urinary metabolite is a compound that is monohydroxylated on the omega minus one carbon atom of the alkyl side chain. A lesser metabolite monohydroxylated on the omega (terminal) position was present in the urine of 6 users of the drug at concentrations of 6–50 μg/L, primarily as a glucuronide conjugate.^{[22][23][24][25][26][27][28][29][30]}

Legal status

JWH-018 powder as it was commonly sold online

Synthesis

Synthesis of JWH-018.^[50]

See also

• AM-2201
• BB-22 (drug)
• JWH-073
• JWH-250
• JWH-200
• PB-22
• SDB-001

References

External links

• JWH-018 Report Psychonaut Web Mapping Research Project
• User of legal high